한빛사
>
한빛사논문
한빛사논문
- 조회224
Biomater. Res., 2024, 28 | https://doi.org/10.34133/bmr.0027
Systemic Treatment with siRNA Targeting Gamma-Secretase Activating Protein Inhibits Amyloid-β Accumulation in Alzheimer's Disease
Sunghwa Kim 1†, Irfan Ullah 1,2†, Jagadish Beloor 1,2, Kunho Chung 1,3, Jongkil Kim 1,4, Yujong Yi 1, Eunhwa Kang 1, Gyeongju Yun 1, Seoyoun Heo 1, Seon-Hong Pyun 1, Seung Hyun Kim 5, Priti Kumar 2, Sang-Kyung Lee 1
1Department of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul, Korea.
2Department of Internal Medicine, Yale University, New Haven, CT, USA.
3Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
4Harvard Medical School, Boston, MA, USA.
5Department of Neurology, College of Medicine, Hanyang University, Seoul, Korea.
†These authors contributed equally to this work.
*Address correspondence to: Sang-Kyung Lee
Abstract
Amyloid-β (Aβ) peptide aggregation in the brain is a key factor in Alzheimer's disease. However, direct inhibition of β-secretase or γ-secretase proves ineffective in reducing Aβ accumulation and improving cognition in Alzheimer's. Recent findings suggest that inhibiting gamma-secretase activating protein (GSAP) can decrease Aβ generation without affecting crucial γ-secretase substrates. Dimerization of Lep9R3LC (diLep9R3LC) was confirmed by Ellman's test. The peptide-small interfering RNA (siRNA) complex ratio, particle size, and surface charge were analyzed using electrophoretic mobility shift assay, and dynamic light scattering, respectively. In a 3xTg mice model of Alzheimer's disease, diLep9R3LC:siRNA complexes were intravenously administered twice a week for 8 weeks. Assessments included gene silencing, protein expression, and behavioral improvement using reverse transcription polymerase chain reaction, quantitative polymerase chain reaction, western blotting, Y-maze, and object recognition tests. The efficacy of Lep9R3LC dimerization was ~80% after a 3-d reaction by Ellman's test. In N2a cells, diLep9R3LC:siGSAP complexes achieved ~70% silencing at 48 h posttransfection. In 7-month-old male 3xTg mice, GSAP knockdown was ~30% in the cortex and ~50% in the hippocampus. The behavior improved in mice treated with diLep9R3LC:siGSAP complexes, showing a 60% increase in entries and an 80% increase object recognition. A novel dipeptide, diLep9R3LC, complexed with siRNA targeting GSAP (siGSAP), efficiently delivers siRNA to the mouse brain, targeting the hippocampus. The treatment inhibits Aβ accumulation, reduces GSK-3β-associated with tau hyperphosphorylation, and improves Alzheimer's behavior. Our findings highlight diLep9R3LC:siGSAP's potential for Alzheimer's and as a siRNA carrier for central nervous system-related diseases.
논문정보
- Research article
- 2024년 06월 (BRIC 등록일 2024-06-17)
- 국내(교신)+국외 연구진
댓글 작성 로그인
팝업 닫기관련 링크
소속기관 논문보기
관련분야 논문보기
